London Daily

Focus on the big picture.
Monday, Jul 21, 2025

Coronavirus: fears the virus is learning how to resist vaccines

Coronavirus: fears the virus is learning how to resist vaccines

US company Novavax reported that its vaccine was nearly 90 per cent effective in clinical trials in Britain, but the figure fell to 49 per cent in South Africa.

New data showing that two Covid-19 vaccines are far less effective in South Africa than in other places they were tested have heightened fears that the coronavirus is quickly finding ways to elude the world’s most powerful tools to contain it.

The US company Novavax reported this week that although its vaccine was nearly 90 per cent effective in clinical trials conducted in Britain, the figure fell to 49 per cent in South Africa – and that nearly all the infections the company analysed in South Africa involved the B. 1.351 variant that emerged there late last year and has spread to the United States and at least 30 other countries.

Johnson & Johnson announced on Friday that its new shot was 72 per cent effective against preventing moderate or severe illness in the United States, compared with 66 per cent in Latin America and 57 per cent in South Africa.

Laboratory tests had suggested that the vaccines authorised in the US – one from Pfizer and BioNTech, the other from Moderna and the National Institutes of Health – trigger a smaller immune response to the South Africa variant.

Now there is evidence from tests in people that some variants are less vulnerable to certain vaccines.

“From an evolutionary biology perspective, this is totally expected and anticipated,” said Dr Michael Mina, a Harvard epidemiologist. “But it never feels good to be validated on something so scary.”

Researchers once believed it would take several more months, or even years, for the virus to develop resistance to vaccines. They said the speedy evolution is largely a result of the virus’ unchecked spread.

More than 100 million people have been infected worldwide, and each of those infections is an opportunity for the virus to randomly mutate.

A mutation that happens to give the virus an advantage – the ability to resist the body’s natural defences, for example – can become the basis for a heartier variant.

One early sign that this process was under way was the significant number of people who were contracting the coronavirus a second time. It appeared that the training their immune systems received during the first infection was failing to protect them from new versions of the virus.

Scientists at Moderna and Pfizer-BioNTech worried that the same thing could happen with immunity induced by their vaccines. In laboratories, they took several versions of the virus and exposed them to blood samples from a small number of people who had been vaccinated.

The neutralising antibodies produced in response to Moderna’s vaccine were equally effective against the original coronavirus and the B.1.1.7 strain that emerged in the United Kingdom but were far less effective against the South Africa strain. Pfizer’s vaccine was only slightly less effective against the South Africa variant compared with the others.

Experts had cautioned that laboratory tests were an imperfect model for understanding the immune response in people.

Other parts of the immune system, such as T-cells, might play a role in fighting a variant, even when neutralising antibodies fall short, said Marc Lipsitch, a Harvard epidemiologist.

That is why the Novavax trial – the first to test the interactions between variants and vaccines in the real world – was so concerning.

“Whether people who have been vaccinated get infected with the variant – that’s the real proof in the pudding,” said Dr Otto Yang, an infectious-disease researcher at UCLA.

Novavax cautioned that its South Africa study, which included about 4,400 patients, was too small to offer a precise measurement on the vaccine’s efficacy.

The Johnson & Johnson results provided further evidence that the problem was serious.

Experts said the weaker performance of the vaccine in South Africa – where it was tested on about 6,500 people – almost certainly was a result of the predominance of the variant circulating widely there. Researchers believe that it is more contagious than other variants and that it has become more common in South Africa and elsewhere since the trial began in September.

Researchers said variants were also likely to blame for the subpar showing of the Johnson & Johnson vaccine in Latin America – where it was tested in more than 17,000 people in Argentina, Brazil, Chile, Colombia, Mexico and Peru.

The mutations of greatest concern are on the spike protein on the surface of the virus, because the current crop of vaccines train the immune system to recognise that protein. Mutations there increase the likelihood that the virus will slip by undetected.


Dr Rochelle Walensky, director of the Centres for Disease Control and Prevention


Mina, the Harvard epidemiologist, likened the process to searching for a criminal by memorising the appearance of only his nose and mouth. At first, this may prove sufficient. But if the criminal gets a nose job, investigators will wish they learned about his eyes, ears and hair as well.

Mina said a more diverse arsenal of vaccines, employing a variety of approaches, is needed.

In the meantime, Moderna has announced efforts to develop a booster shot to add to its current two-shot regimen to fend off the South Africa variant. The company also plans to test whether a third shot of the original formula could help with other strains.

BioNTech, the company that worked with Pfizer on its shot, is also considering developing an adjusted vaccine.

The United States reported its first known cases of the South Africa variant on Thursday, in two people in South Carolina. The UK strain, which is also thought to be more contagious, is also circulating there.


Director of the National Institute of Allergy and Infections Diseases Anthony Fauci


In a briefing for reporters Friday, Dr Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said the confirmation that more transmissible strains are now in the US is a “wake-up call” that underscores the need to rapidly vaccinate Americans.

“Vaccinating as many people as we can, as quickly as we can” is the key to slowing the ability of the virus to mutate, he said. “Viruses cannot mutate if they cannot replicate.”

The US is vaccinating an average of 1.2 million people a day, said Dr Rochelle Walensky, director of the Centres for Disease Control and Prevention.

Experts say that is far too slow, because there’s no knowing what kind of advanced variants will exist by the time the vaccination campaign reaches critical mass.

They stress that vaccination must be accompanied by defensive tactics such as masking and social distancing until case numbers are negligibly low.

“If you think you’re going to simply vaccinate your way out of this, it’s going to be like whack-a-mole,” said Susan Butler-Wu, director of clinical microbiology at LA County-USC Medical Center.

An effective vaccination campaign must eventually stretch around the world. If an impressive strain were to pop up next year in, for example, Brazil, even a fully vaccinated US could be in danger.

“You can vaccinate the hell out of America,” said Mina, but “until everyone is protected, we’re all still at risk.”

Fauci called for bolstering the government’s ability to detect new viral mutations. Genetic sequencing efforts have been fragmented, relying on academics and other groups to voluntarily upload their findings. The US sequences just 1 per cent of the millions of positive samples collected during routine coronavirus testing.

“We’re shining a flashlight around in the dark, hoping we spot dangerous variants,” said Anne Rimoin, an epidemiologist at UCLA. “What we really need to do is flip on the lights.”

Newsletter

Related Articles

0:00
0:00
Close
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
South African Police Minister Suspended Amid Organised Crime Allegations
Nvidia CEO Claims Chinese Military Reluctance to Use US AI Technology
Hong Kong Advances Digital Asset Strategy to Address Economic Challenges
Australia Rules Out Pre‑commitment of Troops, Reinforces Defence Posture Amid US‑China Tensions
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
U.S. Resumes Deportations to Third Countries After Supreme Court Ruling
Excavation Begins at Site of Mass Grave for Children at Former Irish Institution
Iranian President Reportedly Injured During Israeli Strike on Secret Facility
EU Delays Retaliatory Tariffs Amid New U.S. Threats on Imports
Trump Defends Attorney General Pam Bondi Amid Epstein Memo Backlash
Renault Shares Drop as CEO Luca de Meo Announces Departure Amid Reports of Move to Kering
Senior Aides for King Charles and Prince Harry Hold Secret Peace Summit
Anti‑Semitism ‘Normalised’ in Middle‑Class Britain, Says Commission Co‑Chair
King Charles Meets David Beckham at Chelsea Flower Show
If the Department is Really About Justice: Ghislaine Maxwell Should Be Freed Now
NYC Candidate Zohran Mamdani’s ‘Antifada’ Remarks Spark National Debate on Political Language and Economic Policy
×